Literature DB >> 22012551

Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland.

I M Collins, F King, K O'Byrne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22012551     DOI： 10.1007/s11845-011-0772-7

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN： 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  2 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Estimates of the cancer incidence and mortality in Europe in 2006.

Authors:  J Ferlay; P Autier; M Boniol; M Heanue; M Colombet; P Boyle
Journal:  Ann Oncol       Date:  2007-02-07       Impact factor: 32.976
  2 in total
  1 in total

Review 1.  Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.

Authors:  Simon B Zeichner; Daniel A Goldstein; Christine Kohn; Christopher R Flowers
Journal:  J Gastrointest Oncol       Date:  2017-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.